CSIMarket
 
Pulmonx Corporation  (LUNG)
Other Ticker:  
 
 
Price: $8.9500 $0.15 1.705%
Day's High: $9.02 Week Perf: 2.76 %
Day's Low: $ 8.68 30 Day Perf: -38.91 %
Volume (M): 1,131 52 Wk High: $ 14.84
Volume (M$): $ 10,119 52 Wk Avg: $11.56
Open: $8.70 52 Wk Low: $7.75



 Market Capitalization (Millions $) 340
 Shares Outstanding (Millions) 38
 Employees -
 Revenues (TTM) (Millions $) 68
 Net Income (TTM) (Millions $) -61
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 1

Pulmonx Corporation
Pulmonx Corporation is a medical technology company that specializes in developing and commercializing minimally invasive solutions for patients with severe lung diseases. The company focuses on providing innovative treatments for conditions such as chronic obstructive pulmonary disease (COPD) and severe emphysema. Its flagship product is the Zephyr Valve system, which is designed to improve lung function by blocking off diseased lung regions and allowing healthier lung tissue to function more effectively. Pulmonx Corporation is dedicated to improving the quality of life for patients with lung diseases by offering less invasive and highly effective treatment options.


   Company Address: 700 Chesapeake Drive Redwood City 94063 CA
   Company Phone Number: 364-0400   Stock Exchange / Ticker: NASDAQ LUNG
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Pulmonx Corporation

Pulmonx Corporation's Revenue Skyrockets in Q4, 2023

As a financial journalist with the , I have been closely following the latest financial results of Pulmonx Corporation for the fourth quarter of 2023. The company, specializing in minimally invasive treatments for lung disease, has seen some positive improvements in their financial performance compared to the previous year.
One key highlight from the financial results is the decrease in loss per share from $-0.37 to $-0.35, as well as an improvement in earnings per share from $-0.39 in the prior reporting season. The revenue has also shown significant growth, with a rapid increase of 26.12% to $19.45 million from $15.43 million in the similar reporting season a year before.

Pulmonx Corporation

Pulmonx Corporation Sees Impressive Revenue Surge of 26.122% in Q3 2023, But Profitability Remains Elusive

Pulmonx Corporation, a global leader in minimally invasive treatments for lung disease, recently released its financial report for the third quarter of 2023. The report showcased some interesting figures, reflecting the company's growth and challenges.
One remarkable highlight is the surge in revenue by 26.122%, amounting to $17.03 million compared to the previous year's financial reporting period. This growth indicates Pulmonx's ability to attract more customers and generate higher income. However, despite the increase in revenue, the company experienced a widening deficit of $-0.39 per share. This implies that the expenses incurred by Pulmonx are currently exceeding its earnings per share.

Pulmonx Corporation

Pulmonx Corporation Experiences Widening Losses Despite Revenue Growth, Reporting Diminishing Returns Ahead of June 30, 2023 Financial Close

Pulmonx Corporation Reports Increased Loss Per Share and Revenue Growth
Pulmonx Corporation, a leading Medical Equipment & Supplies company, has announced its financial results for the interval ending June 30, 2023. The company reported an increased loss per share of $-0.43, compared to $-0.40 in the same period last year. Additionally, the loss increased from $-0.42 per share in the prior financial reporting period.
On the positive side, Pulmonx Corporation experienced significant revenue growth during this interval. Revenues grew by an impressive 19.957% to $16.73 million, compared to $13.95 million in the corresponding period a year ago. Sequentially, revenue also improved by 15.129% from $14.54 million.

Pulmonx Corporation

Pulmonx Corporation Fails to Find Profit Despite Surging Revenue - Are Their Operations in Jeopardy?

Investing in the stock market is a risky business, and it requires careful consideration before making any significant decisions. The recent financial results of the Medical Equipment & Supplies company and Pulmonx Corporation should caution investors in this sector.
The Medical Equipment & Supplies company saw a significant surge in revenue in the fiscal quarter that ended on March 31, 2023. However, it lost money at $-0.42 per share. The loss of money is significant in the face of the rise in revenue, and it should worry investors. The loss means that the cost of production is higher than the revenue generated from sales. This could be an indication of issues with the company's operations, which could lead to further losses.
In the preceding quarter, the company realized revenue of $15.43 million and $-0.37 per share. The lower revenue and higher loss in the recent quarter could be an indication of future instability in the company. Investors should take this information into account when making investment decisions.
Pulmonx Corporation also experienced a net deficit of $-15.860 million in the most recent fiscal period, which is larger than $-15.828 million in the previous year. A net deficit means that the company is spending more than it is earning, which is a cause for alarm. This could be an indication of poor management, inadequate financial planning, or other underlying issues, which will likely have adverse consequences on the company's future prospects.
Investors interested in Pulmonx Corporation should wait for the upcoming financial reports expected to be released on August 07, 2023, before making any investment decisions. The reports will provide a clearer picture of the company's financial health and performanceIn summary, the recent financial results of the Medical Equipment & Supplies company and Pulmonx Corporation should caution investors wishing to invest in this sector. Investors should look closely at these results and other relevant information before making any significant financial decisions. They should seek the advice of financial experts if necessary and take a cautious approach to avoid incurring losses.






 

Pulmonx's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Pulmonx does not provide revenue guidance.

Earnings Outlook
Pulmonx Corporation does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com